KENGREXAL

Brand name authorized in: Austria Spain Finland France Ireland Lithuania Netherlands Poland United Kingdom

Active ingredients

The drug KENGREXAL contains one active pharmaceutical ingredient (API):

1 Cangrelor
UNII 2144G00Y7W - CANGRELOR TETRASODIUM

Cangrelor is a direct P2Y12 platelet receptor antagonist that blocks adenosine diphosphate (ADP)-induced platelet activation and aggregation in vitro and ex vivo. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signalling and platelet activation.

Read about Cangrelor

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Cangrelor
B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin
Discover more medicines within B01AC25

Medication package inserts

Below package inserts are available for further reading:

Title
Type
Country
Summary of Product Characteristics (SPC)

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
ES
Centro de información online de medicamentos de la AEMPS
Identifier(s): 115994001
FI
Lääkealan turvallisuus- ja kehittämiskeskus
Identifier(s): 125981
FR
Base de données publique des médicaments
Identifier(s): 63207425
GB
Medicines & Healthcare Products Regulatory Agency
Identifier(s): 348664
LT
Valstybinė vaistų kontrolės tarnyba
Identifier(s): 1076044
NL
Z-Index G-Standaard, PRK
Identifier(s): 127590
PL
Rejestru Produktów Leczniczych
Identifier(s): 100342944